Format

Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S75-81. doi: 10.1007/s00259-007-0705-x.

Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography.

Author information

1
Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, München, Germany. G.Henriksen@lrz.tum.de

Abstract

PURPOSE:

The proof of concept for in vivo targeting of beta-amyloid plaques (Abeta) in patients with Alzheimer's disease (AD) by means of nuclear imaging methods has been shown in recent clinical studies.

METHODS:

For positron emission tomography (PET), the five compounds [(11)C]PIB, 3'[(18)F]FPIB, [(18)F]FDDNP, [(11)C]SB-13 and [(18)F]F-SB-13 have been developed by a formal charge neutralisation of agents used for staining of AD brain post mortem.

RESULTS:

In AD-patients, these compounds have been shown to possess a selective uptake in the brain regions known to have a high Abeta-load. Progress towards tracers with proportionality between tracer uptake and quantity of Abeta-load, of use for longitudinal studies of AD patients, is addressed in the current development of Abeta-tracers.

CONCLUSION:

Despite the extensive information on the structure-affinity relationship of several Abeta-binding compounds, data on the regional brain binding kinetics-beyond uptake in healthy rodents-have been obtained only for a few compounds. Recent results indicate that PET-imaging of Abeta-deposits in transgenic rodent models of AD is feasible which may be valuable for a more relevant preclinical evaluation of Abeta-tracers.

PMID:
18224319
DOI:
10.1007/s00259-007-0705-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center